Follow us:
  1. Home
  2. News
  3. Recalls

Glenmark Pharmaceuticals recalls Ranitidine tablets

The medication may be contaminated with a probable cancer-causer

Glenmark Pharmaceutical is recalling all unexpired lots of Ranitidine tablets.

Photo
Photo source: FDA
The product may be contaminated with N-Nitrosodimethylamine (NDMA), a probable human carcinogen, above levels established by the FDA.

Glenmark has not received any reports of adverse events to date.

The following products, used for treatment and prevention of ulcers of the stomach and intestines and treatment of gastroesophageal reflux disease, are being recalled:

NDCDescriptionExpiration Date Range
684620-248-60;
684620-248-01 and
684620-248-05
Ranitidine Tablets, USP 150mg12/2019 – 5/2022
684620-249-30;
684620-249-01 and
684620-249-20
Ranitidine Tablets, USP 300 mg12/2019 – 6/2022

The 150 mg products product are packaged in bottle packs of 60’s, 100’s and 500’s; the 300 mg products are packaged in bottle packs of 30’s, 100’s and 250’s.

What to do

Customers who purchased the recalled products should immediately discontinue use and consult with their physician or healthcare provider about treatment options.

Consumers may call Qualanex at (888) 504-2012, Monday – Friday, 9:00 am – 5:00 pm (EST) to arrange for product return.

Share your comments